--- title: "Innovative pharmaceutical companies receive intensive research from institutions" type: "News" locale: "en" url: "https://longbridge.com/en/news/260522783.md" description: "As of October 9, more than 170 listed companies in the pharmaceutical and biotechnology industry have undergone institutional research, with innovative drug companies such as Mabwell and Gan & Lee receiving significant attention. Institutions are focusing on the R&D investment in innovative drug pipelines, R&D progress, and business development transactions. Institutions believe that the trend of \"innovation + internationalization\" will continue, maintaining a positive outlook on the main line of innovative drugs, and expect new investment opportunities around the 2025 European Society for Medical Oncology" datetime: "2025-10-09T23:31:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/260522783.md) - [en](https://longbridge.com/en/news/260522783.md) - [zh-HK](https://longbridge.com/zh-HK/news/260522783.md) --- # Innovative pharmaceutical companies receive intensive research from institutions Wind data shows that as of October 9, over 170 listed companies in the pharmaceutical and biotechnology industry have undergone institutional research since September. Notably, several innovative pharmaceutical companies, such as Mabwell and Gan & Lee, have received significant attention from institutions. Among the key topics of interest for institutions are R&D investment in innovative drug pipelines, R&D progress, and BD (business development) transactions. Institutions have stated that the industry trend of "innovation + internationalization" will remain unchanged, and they continue to be optimistic about the main line of innovative drugs. It is expected that the upcoming clinical data disclosures and BD transactions related to the European Society for Medical Oncology (ESMO) conference in 2025 will bring new investment opportunities to the sector. (China Securities Journal) ### Related Stocks - [688062.CN](https://longbridge.com/en/quote/688062.CN.md) - [603087.CN](https://longbridge.com/en/quote/603087.CN.md) ## Related News & Research - [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md) - [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md) - [](https://longbridge.com/en/news/286948461.md) - [AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain](https://longbridge.com/en/news/286879044.md) - [BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests](https://longbridge.com/en/news/286850851.md)